CXT29

CXT29 is an orally active COX-2 inhibitor and a thromboxane A2 receptor (TP) antagonist. CXT29 exhibits COX inhibitory activity and selectivity, with IC50 values of 13 and 722 nM for COX-2 and COX-1 respectively. CXT29 inhibits platelet aggregation induced by U-46619 (HY-108566) (a TP agonist), with an IC50 of 96 nM. CXT29 effectively inhibits the production of TXB₂ and PGE₂, significantly reducing platelet aggregation and inflammatory pain in mice. CXT29 can be used for research on inflammatory pain and cardiovascular diseases[1].

Product Specifications

UNSPSC

12352211

Target

COX; Prostaglandin Receptor

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Field of Research

Inflammation/Immunology; Neurological Disease; Cardiovascular Disease

Smiles

CCC(OCC1)(CC(O)=O)C2=C1C3=CC(F)=CC(CC4=CC=CC=C4)=C3N2

Molecular Formula

C22H22FNO3

Molecular Weight

367.41

References & Citations

[1]Blua F, et al. Exploiting the 2- (1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl) acetic Acid Scaffold to Generate COXTRANs: A New Class of Dual Cyclooxygenase Inhibitors-Thromboxane Receptor Antagonists. J Med Chem. 2025 Nov 13;68 (21) :23185-23219.